JNTX 101
Alternative Names: JNTX-101Latest Information Update: 01 Jun 2022
At a glance
- Originator January Therapeutics
- Class Albumins; Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Apr 2022 Preclinical trials in Solid tumours in USA (unspecified route)
- 08 Apr 2022 Pharmacodynamics data from preclinical study in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 01 Jul 2021 January Therapeutics has patents pending for nanoparticle compositions comprising organophosphate compounds and pharmaceutically acceptable carrier such as albumin in Japan, China, European Union, Australia, USA and Canada